Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia

  • STATUS
    Recruiting
  • participants needed
    550
  • sponsor
    Universitätsklinikum Hamburg-Eppendorf
Updated on 7 November 2020
cancer
lymphoid leukemia
cyclophosphamide
methotrexate
cytarabine
mercaptopurine
daunorubicin
asparaginase
pegaspargase
dexamethasone
combination chemotherapy
thioguanine

Summary

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective in treating acute lymphoblastic leukemia. PURPOSE: This randomized phase III trial is studying different combination chemotherapy regimens to compare how well they work in treating young patients with acute lymphoblastic leukemia.

Description

OBJECTIVES: - Determine the dose of daunorubicin hydrochloride that is equivalent to 30 mg/m² of doxorubicin hydrochloride in pediatric patients with acute lymphoblastic leukemia (ALL). - Determine whether it is possible to reduce therapy in pediatric patients with low-risk ALL and a PVA (prednisolone-vincristine-asparaginase) score of 3+4 without loss of efficacy. - Investigate the role of single nucleotide polymorphisms of infection defense gene for infectious complications during therapy in these patients. - Reduce neurological complications by reducing doses of intrathecal methotrexate. - Reduce allergic reactions against asparaginase (ASP) by using pegaspargase after E. coli ASP. OUTLINE: This is a randomized, multicenter study. - Prephase: Patients are randomized to 1 of 3 treatment arms. - Arm I: Patients receive doxorubicin hydrochloride IV once. - Arm II: Patients receive daunorubicin hydrochloride IV once. - Arm III: Patients receive daunorubicin hydrochloride IV once at a higher dose than in arm II. - Induction phase: All patients receive vincristine IV 4 times weekly, daunorubicin hydrochloride IV 3 times weekly, and oral prednisolone daily for 4 weeks. - Intensive phase: Patients are stratified according to risk (low vs high). - Low-risk disease*: Patients receive 4 courses of methotrexate IV and asparaginase intramuscularly (IM). - High-risk disease*: Patients receive 6 courses of cyclophosphamide IV, methotrexate IV, and asparaginase IM. All patients also receive methotrexate IV, teniposide IV, cytarabine IV, high-dose cytarabine IV, and asparaginase IM after completion of the above regimen. - CNS phase: All patients receive intrathecal (IT) methotrexate for 3 doses and oral mercaptopurine for 4 weeks. Patients with T-cell acute lymphoblastic leukemia or patients who have blasts in cerebrospinal fluid at diagnosis or whose WBC > 200/nL at diagnosis OR whose WBC between 100-200/nL at diagnosis and blasts > 1/nL after prephase chemotherapy undergo cranial irradiation. - Reinduction phase: Patients are stratified according to risk (low vs high) - Low-risk disease*: Patients receive 2 courses of doxorubicin hydrochloride IV, vincristine IV, and oral dexamethasone; pegaspargase IM once; and 1 course of cyclophosphamide IV, cytarabine IV, and oral thioguanine. - High-risk disease*: Patients receive 4 courses of doxorubicin hydrochloride IV, vincristine IV, and oral dexamethasone; pegaspargase IM twice; and 2 courses of cyclophosphamide IV, cytarabine IV, and oral thioguanine. - Maintenance phase: All patients receive oral mercaptopurine daily and methotrexate IV once weekly for up to 2 years after diagnosis. NOTE: *In addition to those defined in Disease Characteristics, patients who do not achieve remission after induction phase are treated as high-risk disease, patients who achieve remission after induction phase are treated as low-risk disease PROJECTED ACCRUAL: A total of 550 patients will be accrued for this study.

Details
Condition leukemia
Treatment radiation therapy, cyclophosphamide, methotrexate, cytarabine, doxorubicin hydrochloride, vincristine sulfate, Dexamethasone, Pegaspargase, Mercaptopurine, Prednisolone, Asparaginase, Thioguanine, daunorubicin hydrochloride, teniposide
Clinical Study IdentifierNCT00343369
SponsorUniversitätsklinikum Hamburg-Eppendorf
Last Modified on7 November 2020

Eligibility

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note